January 10, 2018
Amryt to deliver Lojuxta in Central and Eastern Europe via GryNumber Health
Amryt has paved its way for marketing for Lojuxta by signing a deal with with GryNumber Health. The exclusive distribution…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
January 10, 2018
Basilea cashes $3M as it expands Asia Pacific deal for Cresemba with Pfizer
Basilea Pharmaceutica and Pfizer have extended their license agreement for Basilea’s antifungal Cresemba to China and sixteen countries in Asia…
January 10, 2018
Vertex cleared to extend marketing for Orkambi (CF) in Europe
Vertex Pharmaceuticals got European Commission’s grant to extend the Marketing Authorization for ORKAMBI, the first medicine to treat the basic…
January 9, 2018
Novartis moves with clinical trial of Cosentyx vs others, recruiting patients
Novartis has initiated SURPASS, a head-to-head clinical trial of Cosentyx (secukinumab) versus proposed biosimilar adalimumab in ankylosing spondylitis (AS). SURPASS…
January 9, 2018
BASF and CTIBiotech announce first results of 3D human sebaceous glands technology for skin care applications
BASF Care Creations and the Cell Therapy Research Institute CTIBiotech presented the initial results of their joint research on 3D…
January 9, 2018
New Tamper Evident Labeller from LSS
LSS Labelling Systems Scandinavia, a Denmark-based supplier of labelling solutions will launch a new Tamper Evident labelling machine for the pharmaceutical industry at…
January 9, 2018
BD to repurchase its 3.000% notes due 2026
BD has started an offer to repurchase all of its outstanding 3.000% Notes until May 15, 2026 that were issued…
October 3, 2017
FDA accepts sNDA filing for Allergan’s pneumonia drug
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Allergan’s Avycaz (ceftazidime and avibactam) for priority review.
September 29, 2017
FDA OK’s Eli Lilly’s breast cancer drug
The U.S. Food and Drug Administration has approved Eli Lilly’s Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy).
September 27, 2017
Novo Nordisk’s diabetes drug in China
China Food and Drug Administration (CFDA) has approved Novo Nordisk’s Tresiba (insulin degludec) for the treatment of diabetes in China.